SCHEMBL7319285

SCHEMBL7319285

CC(C)(C)OC(=O)NCCc1cn(S(=O)(=O)c2ccccc2)c2ccc(-c3ccc4ccccc4c3)cc12

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.52
NQO2 P16083 1/20 0.48
TNFSF11 O14788 2/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
HTR1E P28566 1/20 0.46
HTR1F P30939 1/20 0.46
HTR7 P34969 1/20 0.46
DRD3 P35462 1/20 0.46
TNF P01375 1/20 0.45
PPARG P37231 2/20 0.44
PPARD Q03181 2/20 0.44
PPARA Q07869 2/20 0.44
IDE P14735 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7309785 0.89 NQO2 (0.48) HTR6NQO2TNFSF11HTR1ADRD2
SCHEMBL7314748 0.89 HTR6 (0.49) HTR6NQO2HTR1ADRD2HTR1D
SCHEMBL7307708 0.88 HTR6 (0.47) HTR6NQO2TNFSF11HTR1ADRD2
SCHEMBL7309156 0.87 HTR6 (0.48) HTR6NQO2HTR1ADRD2HTR1D
SCHEMBL7437268 0.86 HTR6 (0.71) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL7316364 0.86 HTR6 (0.49) HTR6NQO2HTR1ADRD2HTR1D
SCHEMBL7310220 0.85 HTR6 (0.53) HTR6NQO2HTR1ADRD2HTR1D
SCHEMBL7311385 0.81 HTR6 (0.44) HTR6NQO2HTR1ADRD2HTR1D
SCHEMBL7316466 0.80 HTR6 (0.41) HTR6NQO2TNFSF11HTR1ADRD2
SCHEMBL5237100 0.78 HTR6 (0.59) HTR6NQO2HTR1ADRD2HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020004198-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2002-01-10 US disclosed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US disclosed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 HTR6 4503/4885NQO2 1569/4885TNFSF11 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.